Persistence of treatment with conventional systemic agents for patients with psoriasis: a real-world analysis of 73,168 new-users from the French National Health Insurance database (SNDS).
Persistence of treatment with conventional systemic agents for patients with psoriasis: a real-world analysis of 73,168 new-users from the French National Health Insurance database (SNDS).
Br J Dermatol. 2019 Nov 23;:
Authors: Bergqvist C, Mezzarobba M, Weil A, Sbidian E
Abstract
Psoriasis is a chronic inflammatory skin disorder which can have a significant effect on the quality of life1 . There is currently no cure for psoriasis, but there are numerous treatments which are useful in controlling symptoms; thus, long-term treatment is usually required. Conventionals are among the oldest interventions given to clear psoriasis. Treatment persistence, a relevant indicator of therapeutic success2 , has received particular attention in the field of psoriasis, with most studies focusing on the persistence of biologics3,4 .
PMID: 31758801 [PubMed - as supplied by publisher]
Source: The British Journal of Dermatology - Category: Dermatology Authors: Bergqvist C, Mezzarobba M, Weil A, Sbidian E Tags: Br J Dermatol Source Type: research
More News: Databases & Libraries | Dermatology | France Health | Health Insurance | Insurance | Psoriasis | Skin | Study | UK Health